Europe's STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

Explore the investment prospects of 2seventy Bio, a spin-off from bluebird bio, in the competitive field of cell therapies ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

A lawyer for the employers predicts that discovery will show that collusion between drugmakers and PBMs had a significant ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.83% and ...

Brief's Brad Smith and Brian Sozzi examine the top stories on Wall Street, providing investors with a quick overview of what they need to know. Xerox (XRX) is set to acquire Lexmark in a $1.5 billion ...

Discover the first FDA-approved weight loss medication for obstructive sleep apnea, Zepbound by Eli Lilly. Learn how it can reduce apnea events and CPAP market.

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.